Research in the division focuses on conceptual, empirical, and policy-related bioethics research to address emerging challenges in biomedical research and health care. Topic areas include gene sequencing and genetic testing, machine learning and medical decision-making, big data and the learning health system, and access to and equity of care. Our goal is to conduct and facilitate innovative, high-impact empirical bioethics research across the University.
Our current research projects are detailed below. Please also see our Publications.
A major challenge for precision medicine research is including historically under-represented groups in numbers sufficient to ensure statistically valid inferences of the influence of relevant risk factors, including genetic contributions to disease risk. Precision medicine researchers have recognized the critical need to enhance diversity and have implemented a wide variety of approaches to achieve this. All such approaches, however, are shaped by stakeholders’ understandings of what kinds of diversity matter, the local logistical constraints under which precision medicine research is actually being conducted, and the responses of communities to those approaches. Investigating these complex factors from the perspectives of multiple stakeholders in precision medicine research will be essential to effectively address longstanding inequities in genomic and related forms of precision medicine research.
Our study seeks to take advantage of the current proliferation of diversity and inclusion practices to study their heterogeneity, commonalities, and effects on diversifying participation in precision medicine research ("PMR"). We will determine through in-depth analyses of PMR studies how concepts such as definitions of diversity (e.g. genetic ancestry markers, self-reported race and ethnicity) impact practices such as retention, engagement, and return of results. Taking a life course perspective to research relationships, we aim to assess how approaches towards diversity and inclusion are managed in tandem with other research goals and the implications of specific trade-offs that result.
Our study aims are to:
- Identify scientific and sociopolitical justifications for goals of inclusion and conceptual definitions of diversity in precision medicine research;
- Determine how scientific, social, and technical factors influence the operationalization of diversity and implementation of inclusion in precision medicine research; and
- Engage stakeholders to create data-informed guidance that describes the strengths and weaknesses of diversity and inclusion decisions and practices in precision medicine research.
Principal Investigator: Sandra Soo-Jin Lee, PhD
In the emerging era of precision medicine, there have been increasing calls for diversity and the inclusion of historically under-represented racial and ethnic populations in biobanking and precision medicine research. Recent findings suggest that the lack of diversity in genetic repositories may pose serious challenges to identifying genetic variants that are clinically significant in certain populations. These concerns have been linked to ethical concerns over disparities in health and disease among racial and ethnic groups. Despite increasing scrutiny of diversity in recruitment efforts in genomics research, there are few studies that integrate scientific, social, and ethical concerns that are attached to discourse on diversity. This project aims to provide a conceptual framework of diversity that is multi-disciplinary and takes into account the historical and social context in which diversity is invoked in genomics.
The specific aims of this research are:
- To investigate how discourse on human diversity and difference in population based genomics research has changed over time.
- To identify the ethical implications for inclusion of diversity for researcher-participant relationships, including issues related but not limited to “recruitment,” “consent,” “group harm,” and “benefit-sharing."
- To develop a conceptual framework for diversity in genomics research that addresses ethical values of respect, beneficence, and justice.
ELSIhub is a collaboration between Stanford and Columbia Universities and partners at the Hastings Center and Harvard University, whose mission is to enhance the production and use of ELSI research by the ELSI community and other stakeholders. The goal of ELSIhub is to serve as a locus for resource sharing and community building to enhance the production, sharing, and use of research on the ethical, legal, and social implications of genetics and genomics ("ELSI research"), using the “knowledge to action” conceptual framework which highlights facilitators of and barriers to knowledge sharing and use. ELSIhub will be guided by the principles of responsiveness, inclusion, adaptability, rigor, transparency, and open access. It will build in responsiveness to community needs, focusing on ELSI researchers, and incorporating National Human Genome Research Institute and stakeholder input to prioritize services.
The specific aims of ELSIhub are to:
1. Create a platform to identify, collect, index, and share ELSI research products.
2. Provide analytic functions of curation and synthesis of ELSI research on key topics, and mapping the ELSI field.
3. Convene a broad base of stakeholders with relevant expertise to contribute to the development of ELSIhub resources and to address emerging ELSI questions on genomics research.
4. Engage in outreach, dissemination, and training to support the contribution to, and development and use of ELSIhub resources.
Understanding the Expectations and Needs of Diverse Communities for Navigating Research Results (3R01 HG010330-04S1)
Principal Investigator: Sandra Soo-Jin Lee, PhD
Summary: Understanding the preferences and expectations of underrepresented communities for receiving genetic results in a research setting and navigating additional information and services in the clinical setting are critical to building and maintaining research relationships and engendering trust, particularly with groups who have historically not participated in biomedical research. The proposed supplement leverages a unique opportunity to investigate the preferences of African American and Hispanic/Latino communities, including the uninsured, who are being recruited into precision medicine research, for different types of genetic test results and their expectations and needs for information and resources to allow for informed, validated follow-up of research results and clinical care.
Narrative: This application builds on the R01 study the Ethics of Inclusion: Diversity in Precision Medicine Research and aims to investigate the preferences of African American and Hispanic/Latino communities, including the uninsured, who are being recruited into precision medicine research for different types of genetic test results and their expectations and needs for information and resources to allow for informed, validated follow-up of research results and clinical care.
Aims: Identify preferences of patients from underrepresented communities for the return of specific categories of genetic results and their expectations and needs to navigate follow-up care related to the return of research results.
Approach: Stakeholder-based investigation to include individual and group interviews of African American, Hispanic/Latino and/or uninsured individuals.
Longer-term: Inform research guidance and policy.
Navigating Research Results Team:
- Louise Bier, MS, CGC
- Alejandra Aguirre, DrPH, MPH
- Sonia Mendoza-Grey, MPH
- David Goldstein, PhD
- Stephanie M. Fullerton, DPhil
- Emily Vasquez, PhD, MPH
- Melanie Jeske, PhD, MS
- Michael Bentz, MPH
- Nicole Foti, PhD
- Aliya Saperstein, PhD
- Janet K. Shim, PhD, MPP
- Sandra Soo-Jin Lee, PhD
Disability, Diversity and Trust in Precision Medicine Research: Stakeholders Engagement (1R01HG010868)
Principal Investigator: Maya Sabatello, PhD
Summary: People with disabilities comprise the largest health disparities group in the US. Their inclusion in precision medicine research is essential for health benefits to accrue to them and for upholding social justice by treating people with disabilities as equal members of society. Yet, people with disabilities are underrepresented in health research, including precision medicine research, though the reasons for this outcome are understudied. Research shows that trust is key for promoting ethical research and that distrust is a major barrier for participation of racial/ethnic minorities in precision medicine research. However, what constitutes trust and the factors affecting views on trustworthiness of precision medicine research among people with disabilities and translational genomic researchers are understudied, even as such views may be critical for disability inclusive precision medicine research.
Our study engages with people with mobility, visual and hearing disabilities across racial/ethnic communities and with translational genomic researchers to close this gap. We will use a disability, community-based participatory research approach, and Concept Mapping, a multi-step process with mixed-methods design to develop a nuanced conceptual framework for understanding (dis)trust in PMR and an actionable, evidence-based roadmap for enhancing trustworthiness of precision medicine research among people with disabilities.
The study aims are to:
- Identify domains of (dis)trust in and trustworthiness of precision medicine research among people with mobility, vision and hearing disabilities
- Compare sources of (dis)trust in and features of trustworthiness of precision medicine research among people with mobility, vision and hearing disabilities across racial/ethnic groups and between people with mobility, vision and hearing disabilities and translational genomic researchers
- Develop evidence-based recommendations for building trust in precision medicine research among people with mobility, vision and hearing disabilities.
Organizational and Cultural Dynamics in Genomics Companies: Industry Engagement in Navigating Social and Ethical Issues (R00HG010499)
Principal Investigator: Alexis Walker, PhD
Summary: This R00 Award investigates approaches to social and ethical issues within the private sector genomics industry in the US, examining stakeholder perspectives on pathways towards equitable and just outcomes for the field. It does so through methods for both descriptive and normative ethics as well as stakeholder engagement. This includes an investigation of how members of the private sector genomics industry think and talk about the ethical and social dynamics of their work, using interview, survey, and observational methods.
Members of the private sector genomics industry make daily decisions that shape the distribution of the benefits of biomedicine -- from decisions about product pricing to companies’ very understandings of their target customers and markets. With the industry’s central role in shaping how genomic innovations reach the public, perspectives from members of this industry are especially important to possibilities for ethical futures. This study leverages its descriptive examination of stakeholder perspectives to then inform normative analyses and participatory policy and governance planning. In addition to a broad scoping of ethical and social issues as seen from across the industry, the project addresses issues of responsibility, profit, and models of innovation in private sector genomics.
The study aims to:
- Describe the perspectives of individuals working in genomics in the private sector regarding the social and ethical challenges faced in the industry, as well as individuals’ and companies’ responses to these challenges.
- Normatively evaluate the ethics of private profit and social obligation in the genomics industry, based on systematic application of key normative theories in bioethics and business ethics.
- Identify strategic priorities for ethics intervention in private sector genomics, based on a deliberative engagement process with industry stakeholders.
Evidence-based Policy Recommendations to Address Bioethical Challenges in the Return of Genetic Results in Nephrology (3U01DK100876-08S1)
PI: Ali Gharavi, MD; MPI: Maya Sabatello, LLB, PhD
Summary: The return of individual genetic results in nephrology is key for translational genomic efforts to promote patients’ clinical care, but its success hinges largely on the ability of nephrologists and nephrology researchers to implement and facilitate the process. However, no clear policies currently exist about return of genetic results in nephrology research, and no study to date has explored the ethical and practical challenges nephrologists experience in this process. The supplement collaborates with CureGN, a 70-sites consortium dedicated to the return of genetic results for rare renal disorders, and national organizations devoted to cure heritable renal diseases, to investigate the experiences of nephrology healthcare providers in returning genetic results from research.
- Aim 1: Identify overarching ethical and practical challenges in return of genetic results in nephrology research and possible remedies for these challenges by surveying adult and pediatric nephrologists and other nephrology providers
- Aim 2: conduct an iterative process to develop recommendations for return of genetic results from nephrology research.
- Hila Milo Rasouly, PhD
- Maddalena Marasa, MD
- Olivia A. Balderes, MA
- Victoria Kolupaeva, PhD
- Maya Sabatello, LLB, PhD
- Ali Gharavi, MD
Leveraging Tumor Registries and Pathology Specimens to Facilitate Genetic Testing and Tracebackfor Ovarian Cancer (5U01CA244323-02)
PI: Jessica Ezzell Hunter, PhD; Site PI, Sandra Soo-Jin Lee, PhD (NCI)
Summary: An estimated 1 in 190 women carry a pathogenic variant in BRCA1/2, which is associated with a 46-57% risk of breast cancer and 20-40% risk of ovarian cancer by age 70. Carriers account for 10% and 15% of breast and ovarian cancer cases, respectively, and up to 20% of high-grade serous ovarian cancer cases, the most aggressive subtype. Despite recommendations that all ovarian cancer cases should receive genetic counseling and testing, irrespective of family history and age at onset, a recent national study indicated that only 10% of cases underwent genetic testing. This represents a missed opportunity to inform these women and their at-risk family members about their future cancer risk. Our multidisciplinary team marshals expertise in bioethics, genetic epidemiology, genomic medicine, biostatistics, health communication, and medical genetics to address the ethical, regulatory, and scientific challenges to address challenges in applying a traceback testing approach to retrospectively identify women who have a prior diagnosis of ovarian cancer. This study generates evidence on the feasibility of traceback testing using tumor registries and archived pathology samples that are critically important to guide the future implementation of such programs beyond ovarian cancer.